ImmunoScape
PrivateLast Round
Strategic
Mar 4, 2026
Est. Valuation
$37.9M
Total Funding Raised
$39M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
ImmunoScape operates in Healthcare & Life Sciences and is based in Singapore. Its latest recorded funding round was a Strategic round in March 2026.
ImmunoScape is a biotechnology company that discovers and develops next-generation T-cell receptor (TCR) cell therapies in the field of oncology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Government Contracts
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ImmunoScape Comparables
Compare ImmunoScape with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Lion TCR | 86% | |
| BlueSphere Bio | 84% | |
| 3T Biosciences | 83% |
For institutional investors. Book with your work email.
ImmunoScape Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Mar 4, 2026 | ||||
| Series B Extension | Sep 20, 2022 | ||||
| Series A Extension | Apr 14, 2021 | ||||
| Series A | Aug 12, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
ImmunoScape Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| UTEC (The University of Tokyo Edge Capital Partners) | Series A, Series A Extension |
| EDBI | Series B Extension, Series A Extension |
| Amgen Ventures | Series B Extension |
| Anzu Partners | Series B Extension, Series A, Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 16, 2026
Partnering to develop a breakthrough cell therapy for solid tumors.
- Mar 4, 2026
Leonardo DiCaprio participated in the round.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 23, 2026
On Sep 23rd '26, ImmunoScape Pte Ltd is positioning its leadership team for the next development stage of its TCR-based cancer immunotherapy platform, with Olagunju overseeing corporate and clinical execution and Fehlings directing scientific and technical strategy.
- hiresSep 23, 2026
ImmunoScape Pte Ltd appoints Peter Olagunju as Chief Executive Officer in Singapore on Sep 23rd '26, as it prepares to advance its Seed and Boost cancer immunotherapy platform into the clinic.
For institutional investors. Book with your work email.
ImmunoScape Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ImmunoScape's valuation, stock price, and market status.
Is ImmunoScape a public or private company?
ImmunoScape is a private company.
What is the current stock price of ImmunoScape?
ImmunoScape is a private company, so its shares have no public market price. Caplight tracks ImmunoScape's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ImmunoScape worth (valuation)?
ImmunoScape's valuation is estimated at $37.9M based on funding round data.
Can I buy ImmunoScape stock?
ImmunoScape shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ImmunoScape's last funding round?
ImmunoScape's most recent funding round was Strategic on March 4, 2026.
Who are the main investors in ImmunoScape?
Key investors in ImmunoScape include UTEC (The University of Tokyo Edge Capital Partners), EDBI, Anzu Partners.
Will ImmunoScape IPO soon?
No public IPO plans have been announced for ImmunoScape.
How can I track ImmunoScape secondary market activity?
Caplight tracks bids, offers, and trades in ImmunoScape's shares on secondary markets.